Affinity Disabilities Pty Ltd T/A Affinity Disability Services is facing a s.394 (Application for unfair dismissal remedy) before Fair Work Deputy President Asbury in Chambers in Brisbane (Lappin)
January 19, 2023
The Australian Salaried Medical Officers Federation and Goulburn Valley Health T/A GV Health & Ms Olivia Gallace have a s.739 (Application to deal with a dispute) on foot before Fair Work Commissioner Yilmaz in Court 3 – Level 6, Conference Room B – Level 6 in Melbourne
January 18, 2023
The Dept of Health & Human Services Victoria is facing a s.394 (Application for unfair dismissal remedy) before Commissioner Wilson (video using Microsoft Teams) in Melbourne (Woods)
January 16, 2023
Elder Rights Advocacy has appointed Debra Nicholl as its chief executive officer and Janis Porter its new president.
January 16, 2023
Brightwater has appointed Kellie Benda as a non-executive director of the Brightwater Care Group Board.
January 13, 2023
Kayda Care will have to address a s.394 (Application for unfair dismissal remedy) before Fair Work Deputy President Bell (video using Microsoft Teams) in Melbourne today (Hughes)
January 13, 2023
Ann Peacock, the public face of Melbourne’s Crown since its inception in the mid 1990s, is stepping down from the role. After holding senior positions for 29 years, Ms Peacock has decided to focus on pursuing charitable work and passions including a new board role on the Victoria Racing Club. During her tenure, Ms Peacock has been instrumental in philanthropic initiatives which have raised tens of millions of dollars for causes across the state. “I’m incredibly proud of what we’ve achieved. It’s been a privilege to be part of Crown since opening, managing public relations, entertainment, stakeholder management and philanthropy and charity interests,” she said. “With the recent change of ownership of Crown, it’s an appropriate time for me to hand the reins on.”
January 13, 2023
Medicinal cannabis company Cann Group has appointed former AstraZeneca senior manager Peter Koetsier as its new chief executive officer. The senior pharma executive will begin his new role on January 16, replacing Peter Crock who announced on October 24 last year that he would depart his role after more than six years as head of the company. Mr Koetsier will lead Cann with his more than 30 years of experience in global pharmaceutical companies, including his time as Asia Pacific Head for French biopharmaceutical company Ipsen, AstraZeneca and Bristol Myers Squibb. The incoming chief executive will earn an annual gross base salary of $350,000 and 4.5 million shares through the company’s employees options scheme. “I have a strong interest in new therapeutic areas and see tremendous potential for medicinal cannabis,” Mr Koetsier said. “Cann has established a genetics and production/ manufacturing base that is world class.” Cann shares closed up 2.4 per cent at 21c.
